Tag Archives: NASDAQ:ADVM
Raymond James Sticks to Its Hold Rating for Adverum Biotechnologies (ADVM)
In a report issued on May 28, Dane Leone from Raymond James maintained a Hold rating on Adverum Biotechnologies (ADVM – Research Report). The company’s shares closed last Tuesday at $12.91. According to TipRanks.com, Leone is a 5-star analyst with
Adverum Biotechnologies (ADVM) Received its Third Buy in a Row
After SunTrust Robinson and Piper Sandler gave Adverum Biotechnologies (NASDAQ: ADVM) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies today. The company’s shares
Chardan Capital Keeps a Buy Rating on Adverum Biotechnologies (ADVM)
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies (ADVM – Research Report) on May 5 and set a price target of $20.00. The company’s shares closed last Friday at $19.59. According to TipRanks.com, Amusa is a
Adverum Biotechnologies (ADVM) Receives a Buy from Chardan Capital
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies (ADVM – Research Report) today. The company’s shares closed last Monday at $11.07. According to TipRanks.com, Amusa is a top 100 analyst with an average return of 22.2%
Adverum Biotechnologies (ADVM) Gets a Buy Rating from Chardan Capital
Chardan Capital analyst Gbola Amusa reiterated a Buy rating on Adverum Biotechnologies (ADVM – Research Report) yesterday and set a price target of $20.00. The company’s shares closed last Monday at $10.50. According to TipRanks.com, Amusa is a top 100
Cowen & Co. Maintains Their Buy Rating on Adverum Biotechnologies (ADVM)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Adverum Biotechnologies (ADVM – Research Report). The company’s shares closed last Monday at $7.94. According to TipRanks.com, Nadeau is a 5-star analyst with an
